Mesenchymal stromal cells protect combined oncolytic and helper-dependent adenoviruses from humoral immunity DOI Creative Commons

Ada Ozcan,

Arianexys Aquino Lόpez,

A Wolff

et al.

Molecular Therapy — Methods & Clinical Development, Journal Year: 2024, Volume and Issue: 32(3), P. 101279 - 101279

Published: June 6, 2024

Language: Английский

Antibodies against adenoviruses DOI

Ronald Vogels,

Jerome Custers

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 243 - 273

Published: Jan. 1, 2025

Citations

0
Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects: Update from 2015 review DOI Creative Commons
Leah A. Marquez‐Curtis,

Janet A.W. Elliott

Cryobiology, Journal Year: 2024, Volume and Issue: 115, P. 104856 - 104856

Published: Feb. 8, 2024

Mesenchymal stromal cells (MSCs) have become one of the most investigated and applied for cellular therapy regenerative medicine. In this update our review published in 2015, we show that studies continue to abound regarding characterization MSCs distinguish them from other similar cell types, discovery new tissue sources MSCs, confirmation their properties functions render suitable as a therapeutic. Because cryopreservation is widely recognized only technology would enable on-demand availability here although traditional method cryopreserving by slow cooling presence 10% dimethyl sulfoxide (Me2SO) continues be used many, several novel MSC approaches emerged. As previous review, conclude these recent reports viable functional diverse tissues can recovered after using variety cryoprotectants, freezing protocols, storage temperatures, periods storage. We also logistical reasons there are now more devoted which derived. A topic included covers application COVID-19 arising immunomodulatory antiviral properties. Due inherent heterogeneity populations different still no standardized procedure isolation, identification, characterization, cryopreservation, route administration, not likely "one-size-fits-all" approach applications cell-based

Language: Английский

Citations

3
Syngeneic mesenchymal stem cells loaded with telomerase-dependent oncolytic adenoviruses enhance anti-metastatic efficacy DOI Creative Commons

Mei-Lin Yang,

Che‐Yuan Hu,

Ya-Che Lee

et al.

Stem Cells Translational Medicine, Journal Year: 2024, Volume and Issue: 13(8), P. 738 - 749

Published: June 12, 2024

Abstract Oncolytic adenoviruses have emerged as a promising therapeutic approach for cancer therapy. However, systemic delivery of the viruses to metastatic tumors remains major challenge. Mesenchymal stem cells (MSCs) possess tumor tropism property and can be used cellular vehicles delivering oncolytic sites. Since telomerase activity is found in ~90% human carcinomas, but undetected normal adult cells, reverse transcriptase gene (TERT) promoter exploited regulating replication adenoviruses. Here, we evaluated antitumor effects syngeneic murine MSCs loaded with luciferase-expressing, telomerase-dependent adenovirus Ad.GS2 (MSC-Ad.GS2) alone on MBT-2 bladder tumors. supported low degree replication, which could augmented by coculture or tumor-conditioned medium (TCM), suggesting that viral increased when MSC-Ad.GS2 migrates TCM enhanced Ad.GS2-infected MSCs. SDF-1 cell homing factor. Our results suggest SDF-1/STAT3/TERT signaling axis response microenvironment may contribute carried Notably, demonstrate potent efficacy systemically delivered pleural disseminated experimental metastasis models using intrapleural tail vein injection respectively. Treatment significantly reduced growth prolonged survival mice bearing expressed broad spectrum cancers, this strategy broadly applicable.

Language: Английский

Citations

2
Mesenchymal-Stem-Cell-Based Therapy against Gliomas DOI Creative Commons

Sisa M. Santillán-Guaján,

Mehdi Hayat Shahi, Javier S. Castresana

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(7), P. 617 - 617

Published: April 2, 2024

Glioblastoma is the most aggressive, malignant, and lethal brain tumor of central nervous system. Its poor prognosis lies in its inefficient response to currently available treatments that consist surgical resection, radiotherapy, chemotherapy. Recently, use mesenchymal stem cells (MSCs) as a possible kind cell therapy against glioblastoma gaining great interest due their immunomodulatory properties, tropism, differentiation into other types. However, MSCs seem present both antitumor pro-tumor properties depending on tissue from which they come. In this work, possibility using deliver therapeutic genes, oncolytic viruses, miRNA presented, well strategies can improve efficacy glioblastoma, such CAR-T cells, nanoparticles, exosomes.

Language: Английский

Citations

2
Cationic Liposomes Overcome Neutralizing Antibodies and Enhance Reovirus Efficacy in Ovarian Cancer DOI

Zhiru Yang,

Liang Chen, Ting Guo

et al.

Virology, Journal Year: 2024, Volume and Issue: 598, P. 110196 - 110196

Published: July 31, 2024

Language: Английский

Citations

2
Mesenchymal stromal cells protect combined oncolytic and helper-dependent adenoviruses from humoral immunity DOI Creative Commons

Ada Ozcan,

Arianexys Aquino Lόpez,

A Wolff

et al.

Molecular Therapy — Methods & Clinical Development, Journal Year: 2024, Volume and Issue: 32(3), P. 101279 - 101279

Published: June 6, 2024

Language: Английский

Citations

0